Edgar-8K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: July 8, 2015
(Date of earliest event reported)
ImmuCell Corporation
(Exact name of registrant as specified in its charter)
DE 001-12934 01-0382980
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
56 Evergreen Drive, Portland, Maine 04103
(Address of principal executive offices) (Zip Code)
207-878-2770
(Registrant's telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure
On July 8, 2015, ImmuCell Corporation (the "Company") publicly disclosed an increase in its sales guidance for the second quarter of 2015. This is discussed in greater detail in today's press release, which is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Press Release of ImmuCell Corporation dated July 8, 2015
Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 8, 2015 ImmuCell Corporation

By: /s/ Michael F. Brigham
     Michael F. Brigham
     President, Chief Executive Officer and Principal Financial Officer
Exhibit Index